| Program |
Resources |
| Biopharmaceutical Development Program |
Offers resources for and expertise in the
development of investigational biological products that move promising treatments for
cancer, rare diseases, HIV/AIDS, and other infectious diseases into clinical trials.
|
| Cancer Prevention Clinical Trials Network (CP-CTNet) |
CP-CTNet performs early phase clinical
trials to assess the safety, tolerability, and cancer preventive potential of agents and
interventions. |
| Cancer Systems Biology Consortium (CSBC) |
The multidisciplinary Cancer Systems
Biology Consortium (CSBC), which includes cancer biologists, engineers, mathematicians,
physicists, and oncologists, aims to tackle the most perplexing issues in cancer to increase
our understanding of tumor biology, treatment options, and patient outcome. |
| Cooperative Human Tissue Network (CHTN) |
The CHTN is a unique NCI supported resource
that provides human tissues and fluids from routine procedures to investigators who utilize
human biospecimens in their research. |
| DTP Repository |
Developmental Therapeutics Program (DTP)
supports a number of Repositories for the acquisition, storage and distribution of chemical,
and biological samples and standards to researchers worldwide. |
| Human Cancer Models Initiative (HCMI) |
The goal of HCMI is to create up to 1,000
patient-derived next-generation cancer models (NGCMs) such as organoids, conditionally
reprogrammed cells, neurospheres, or optimal growth condition models as a community
resource. |
| Moonshot Biobank |
The Cancer Moonshot Biobank is a 5-year
project to learn more about cancer with the help of participants who donate samples as they
receive treatment. |
| NCI Formulary |
A public-private partnership between the
NCI and pharmaceutical and biotechnology companies that provides NCI funded main-member
ETCTN and NCTN institutions in the United States and their investigators rapid access to
agents for cancer clinical trial use or to any investigators for preclinical research. |
| NCI Liver Cancer
Program |
A multidisciplinary network of researchers
and clinicians dedicated to improving early detection, diagnosis, prognosis and treatment of
liver cancer. |
| NCI Patient-Derived Models Repository (PDMR) |
A national repository of Patient-Derived
Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor
cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived
organoids (PDOrg). |
| NCI PREVENT Program |
A peer-reviewed agent development program
designed to support preclinical development of innovative interventions and biomarkers for
cancer prevention and interception towards clinical trials. |
| NExT Program |
NExT provides resources for projects
focused on developing therapies for unmet medical needs in the area of oncology that are not
typically addressed by the private sector. NExT is NOT a grant mechanism. |
| NIH STRIDES Initiative |
The STRIDES Initiative aims to help NIH and
its institutions accelerate biomedical research by reducing barriers in utilizing commercial
cloud services. This initiative aims to harness the power of the cloud to accelerate
biomedical discovery. NIH and NIH-funded researchers can take advantage of STRIDES benefits.
|
| The Cancer Imaging Archive
(TCIA) |
TCIA is a service which de-identifies and
hosts a large archive of medical images of cancer accessible for public download. |
| The NCI Program for Natural Product Discovery (NPNPD) |
A library of partially-purified natural
product fractions more amenable for use in high-throughput screening. Publicly accessible,
free of charge, and open to screening against all disease targets. Launched in 2019. As of
March 2023, 500,000 natural product fractions are available |
| The Stepping Stones Program |
This initiative is intended to augment
grant-supported programs with access to NCI/DCTD/DTP drug development capabilities to fill
knowledge and data gaps, thus enabling these programs to advance and procure additional
resources for development toward clinical testing. |